TipRanks
Sarepta Therapeutics (CH:AB3A)
:AB3A
Switzerland Market
AB3A
Sarepta Therapeutics
RESEARCH TOOLSreports

Sarepta Therapeutics (AB3A) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

AB3A Analyst Ratings

Hold
17Ratings
Hold
4 Buy
9 Hold
4 Sell
Based on 17 analysts giving stock ratings to
Sarepta
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AB3A Stock 12 Month Forecast

Average Price Target

―
Based on 17 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is CHF18.48 with a high forecast of CHF31.51 and a low forecast of CHF4.15. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF31.51Average Price TargetCHF18.48Lowest Price TargetCHF4.15
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on CH:AB3A
Gil Blum
Needham
Needham
―
Sell
―
Reiterated
09/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), BioNTech SE (NASDAQ: BNTX) and AgomAb Therapeutics NV ADR (NASDAQ: AGMB)
William Blair Analyst forecast on CH:AB3A
Lachlan Hanbury Brown
William Blair
William Blair
―
Hold
―
Reiterated
09/28/26
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
Citi Analyst forecast on CH:AB3A
Yigal Nochomovitz
Citi
Citi
CHF10.78
Sell
―
Reiterated
09/27/26
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
J.P. Morgan Analyst forecast on CH:AB3A
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
09/15/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Addus Homecare (NASDAQ: ADUS) and Perspective Therapeutics (NYSE MKT: CATX)
H.C. Wainwright Analyst forecast on CH:AB3A
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF4.15
Sell
―
Reiterated
09/09/26
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
Wedbush Analyst forecast on CH:AB3A
Yun Zhong
Wedbush
Wedbush
CHF29.02
Buy
―
Reiterated
09/08/26
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
Evercore ISI Analyst forecast on CH:AB3A
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF15.76
Hold
―
Reiterated
08/10/26
Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Barclays Analyst forecast on CH:AB3A
Eliana Merle
Barclays
Barclays
CHF16.59
Hold
―
Reiterated
08/07/26
Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
TD Cowen Analyst forecast on CH:AB3A
Ritu Baral
TD Cowen
TD Cowen
CHF14.1
Hold
―
Assigned
08/06/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX), Black Diamond Therapeutics (NASDAQ: BDTX) and Sarepta Therapeutics (NASDAQ: SRPT)
Wells Fargo Analyst forecast on CH:AB3A
Yanan Zhu
Wells Fargo
Wells Fargo
CHF31.51
Buy
―
Reiterated
08/06/26
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
Bank of America Securities Analyst forecast on CH:AB3A
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF15.76→CHF14.93
Sell
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)
Piper Sandler Analyst forecast on CH:AB3A
Biren Amin
Piper Sandler
Piper Sandler
CHF16.59
Hold
―
Reiterated
08/06/26
Sarepta Therapeutics (SRPT) Receives a Hold from Piper Sandler
Morgan Stanley Analyst forecast on CH:AB3A
Michael Ulz
Morgan Stanley
Morgan Stanley
CHF20.73
Hold
―
Assigned
08/06/26
Morgan Stanley Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
Oppenheimer Analyst forecast on CH:AB3A
Kostas Biliouris
Oppenheimer
Oppenheimer
CHF30.68→CHF29.02
Buy
―
Reiterated
08/06/26
Sarepta price target lowered to $35 from $37 at OppenheimerSarepta price target lowered to $35 from $37 at Oppenheimer
Cantor Fitzgerald Analyst forecast on CH:AB3A
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF17.41
Hold
―
Reiterated
08/05/26
Cantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on CH:AB3A
Gil Blum
Needham
Needham
―
Sell
―
Reiterated
09/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), BioNTech SE (NASDAQ: BNTX) and AgomAb Therapeutics NV ADR (NASDAQ: AGMB)
William Blair Analyst forecast on CH:AB3A
Lachlan Hanbury Brown
William Blair
William Blair
―
Hold
―
Reiterated
09/28/26
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
Citi Analyst forecast on CH:AB3A
Yigal Nochomovitz
Citi
Citi
CHF10.78
Sell
―
Reiterated
09/27/26
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
J.P. Morgan Analyst forecast on CH:AB3A
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
09/15/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Addus Homecare (NASDAQ: ADUS) and Perspective Therapeutics (NYSE MKT: CATX)
H.C. Wainwright Analyst forecast on CH:AB3A
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF4.15
Sell
―
Reiterated
09/09/26
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
Wedbush Analyst forecast on CH:AB3A
Yun Zhong
Wedbush
Wedbush
CHF29.02
Buy
―
Reiterated
09/08/26
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
Evercore ISI Analyst forecast on CH:AB3A
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF15.76
Hold
―
Reiterated
08/10/26
Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Barclays Analyst forecast on CH:AB3A
Eliana Merle
Barclays
Barclays
CHF16.59
Hold
―
Reiterated
08/07/26
Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
TD Cowen Analyst forecast on CH:AB3A
Ritu Baral
TD Cowen
TD Cowen
CHF14.1
Hold
―
Assigned
08/06/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX), Black Diamond Therapeutics (NASDAQ: BDTX) and Sarepta Therapeutics (NASDAQ: SRPT)
Wells Fargo Analyst forecast on CH:AB3A
Yanan Zhu
Wells Fargo
Wells Fargo
CHF31.51
Buy
―
Reiterated
08/06/26
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
Bank of America Securities Analyst forecast on CH:AB3A
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF15.76→CHF14.93
Sell
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)
Piper Sandler Analyst forecast on CH:AB3A
Biren Amin
Piper Sandler
Piper Sandler
CHF16.59
Hold
―
Reiterated
08/06/26
Sarepta Therapeutics (SRPT) Receives a Hold from Piper Sandler
Morgan Stanley Analyst forecast on CH:AB3A
Michael Ulz
Morgan Stanley
Morgan Stanley
CHF20.73
Hold
―
Assigned
08/06/26
Morgan Stanley Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
Oppenheimer Analyst forecast on CH:AB3A
Kostas Biliouris
Oppenheimer
Oppenheimer
CHF30.68→CHF29.02
Buy
―
Reiterated
08/06/26
Sarepta price target lowered to $35 from $37 at OppenheimerSarepta price target lowered to $35 from $37 at Oppenheimer
Cantor Fitzgerald Analyst forecast on CH:AB3A
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF17.41
Hold
―
Reiterated
08/05/26
Cantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OVIDOvid Therapeutics
ESTAEstablishment Labs Holdings
LGNDLigand Pharma
KURAKura Oncology
ZYMEZymeworks
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

3 Months
Mitchell KapoorH.C. Wainwright
Success Rate
13/17 ratings generated profit
76%
Average Return
+11.35%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +11.35% per trade.
1 Year
Mitchell KapoorH.C. Wainwright
Success Rate
13/17 ratings generated profit
76%
Average Return
+19.07%
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +19.07% per trade.
2 Years
Mitchell KapoorH.C. Wainwright
Success Rate
12/17 ratings generated profit
71%
Average Return
+17.26%
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +17.26% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AB3A Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
16
8
6
5
5
Buy
4
1
2
1
1
Hold
18
12
13
13
14
Sell
7
2
4
4
6
Strong Sell
4
2
3
3
4
total
49
25
28
26
30
In the current month, AB3A has received 6 Buy Ratings, 14 Hold Ratings, and 10 Sell Ratings. AB3A average Analyst price target in the past 3 months is 18.48.
Each month's total comprises the sum of three months' worth of ratings.

AB3A Financial Forecast

AB3A Earnings Forecast

Next quarter’s earnings estimate for AB3A is CHF0.13 with a range of -CHF0.42 to CHF0.70. The previous quarter’s EPS was -CHF0.04. AB3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AB3A has Performed in-line its overall industry.
Next quarter’s earnings estimate for AB3A is CHF0.13 with a range of -CHF0.42 to CHF0.70. The previous quarter’s EPS was -CHF0.04. AB3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AB3A has Performed in-line its overall industry.

AB3A Sales Forecast

Next quarter’s sales forecast for AB3A is CHF294.50M with a range of CHF277.06M to CHF326.43M. The previous quarter’s sales results were CHF333.96M. AB3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AB3A has Performed in-line its overall industry.
Next quarter’s sales forecast for AB3A is CHF294.50M with a range of CHF277.06M to CHF326.43M. The previous quarter’s sales results were CHF333.96M. AB3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AB3A has Performed in-line its overall industry.

AB3A Stock Forecast FAQ

What is CH:AB3A’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 18.48.
    What is CH:AB3A’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:AB3A, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Sarepta Therapeutics a Buy, Sell or Hold?
        Sarepta Therapeutics has a consensus rating of Hold, which is based on 4 buy ratings, 9 hold ratings and 4 sell ratings.
          What is Sarepta Therapeutics’s share price target?
          The average share price target for Sarepta Therapeutics is 18.48. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF31.51 ,and the lowest forecast is CHF4.15. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Sarepta Therapeutics?
            Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 17 Wall Streets Analysts.
              How can I buy shares of Sarepta Therapeutics?
              To buy shares of CH:AB3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.